Biogen Idec Given a $300.00 Price Target at Leerink Swann (BIIB)
Equities research analysts at Leerink Swann set a $300.00 price objective on shares of Biogen Idec (NASDAQ:BIIB) stock in a research note issued to investors on Monday, StockRatingsNetwork.com reports. Leerink Swann’s price objective indicates a potential upside of 24.84% from the company’s current price.
A number of other analysts have also recently weighed in on BIIB. Analysts at TheStreet reiterated a “buy” rating on shares of Biogen Idec in a research note to investors on Wednesday, October 2nd. Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of Biogen Idec in a research note to investors on Wednesday, October 2nd. They now have a $290.00 price target on the stock, up previously from $255.00. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of Biogen Idec from $220.00 to $240.00 in a research note to investors on Wednesday, September 18th. Eight analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Biogen Idec currently has an average rating of “Buy” and a consensus target price of $253.14.
Biogen Idec (NASDAQ:BIIB) opened at 237.35 on Monday. Biogen Idec has a one year low of $134.00 and a one year high of $248.95. The stock’s 50-day moving average is $229.1 and its 200-day moving average is $217.1. The company has a market cap of $56.411 billion and a price-to-earnings ratio of 35.59.
Biogen Idec (NASDAQ:BIIB) last released its earnings data on Thursday, July 25th. The company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.37. The company had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.62 billion. During the same quarter in the previous year, the company posted $1.82 earnings per share. The company’s revenue for the quarter was up 21.3% on a year-over-year basis. Analysts expect that Biogen Idec will post $8.59 EPS for the current fiscal year.
Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.